March 25th 2025
The approval marks a vital step toward care for urinary tract infections, helping to reduce recurrence and improve patients’ quality of life.
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment
View More
'It's about time,' fezolinetant approval and latest research showcased at annual meeting
May 19th 2023Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.
Watch
FDA approves dostarlimab for dMMR endometrial cancer
February 10th 2023The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read More
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
Read More
FDA approves IUD to prevent pregnancy for up to 8 years
November 15th 2022The Food and Drug Administration (FDA) has approved Medicine360’s supplemental new drug application to extend the use of its levongestrel-releasing intrauterine system 52mg (LILETTA) to prevent pregnancy for up to 8 years.
Read More